Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 2
2019 1
2020 1
2023 3
2024 4
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Expanding Xpert MTB/RIF Ultra® and LF-LAM testing for diagnosis of tuberculosis among HIV-positive adults admitted to hospitals in Tanzania and Mozambique: a randomized controlled trial (the EXULTANT trial).
Mangu C, Cossa M, Ndege R, Khosa C, Leukes V, de la Torre-Pérez L, Machiana A, Kivuma B, Mnzava D, Zachariah C, Manjate P, Tagliani E, Schacht C, Buech J, Singh S, Ehrlich J, Riess F, Sanz S, Kranzer K, Cox H, Sabi I, Nguenha D, Meggi B, Weisser M, Ntinginya N, Schumacher S, Ruhwald M, Penn-Nicholson A, Garcia-Basteiro AL; TB-CAPT Consortium. Mangu C, et al. BMC Infect Dis. 2024 Aug 15;24(1):831. doi: 10.1186/s12879-024-09651-z. BMC Infect Dis. 2024. PMID: 39148008 Free PMC article. Clinical Trial.
Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study.
Olbrich L, Franckling-Smith Z, Larsson L, Sabi I, Ntinginya NE, Khosa C, Banze D, Nliwasa M, Corbett EL, Semphere R, Verghese VP, Michael JS, Ninan MM, Saathoff E, McHugh TD, Razid A, Graham SM, Song R, Nabeta P, Trollip A, Nicol MP, Hoelscher M, Geldmacher C, Heinrich N, Zar HJ; RaPaed-AIDA-TB consortium. Olbrich L, et al. Lancet Infect Dis. 2025 Feb;25(2):188-197. doi: 10.1016/S1473-3099(24)00494-8. Epub 2024 Sep 20. Lancet Infect Dis. 2025. PMID: 39312914 Free article.
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries.
Olbrich L, Verghese VP, Franckling-Smith Z, Sabi I, Ntinginya NE, Mfinanga A, Banze D, Viegas S, Khosa C, Semphere R, Nliwasa M, McHugh TD, Larsson L, Razid A, Song R, Corbett EL, Nabeta P, Trollip A, Graham SM, Hoelscher M, Geldmacher C, Zar HJ, Michael JS, Heinrich N; RaPaed-TB consortium. Olbrich L, et al. Lancet Infect Dis. 2024 Feb;24(2):140-149. doi: 10.1016/S1473-3099(23)00491-7. Epub 2023 Oct 30. Lancet Infect Dis. 2024. PMID: 37918414 Free PMC article.
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, Noreña I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N; PanACEA consortium. Koele SE, et al. Among authors: manyama c. J Antimicrob Chemother. 2025 Aug 1;80(8):2305-2313. doi: 10.1093/jac/dkaf210. J Antimicrob Chemother. 2025. PMID: 40613338 Free PMC article. Clinical Trial.
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.
Heinrich N, Manyama C, Koele SE, Mpagama S, Mhimbira F, Sebe M, Wallis RS, Ntinginya N, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Stoycheva K, Zumba T, Noreña I, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut J, Aarnoutse RE, McHugh TD, Wildner L, Boeree M, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM; PanACEA consortium. Heinrich N, et al. Among authors: manyama c. Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00213-0. doi: 10.1016/S1473-3099(25)00213-0. Online ahead of print. Lancet Infect Dis. 2025. PMID: 40645196 Free article.
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Heinrich N, de Jager V, Dreisbach J, Gross-Demel P, Schultz S, Gerbach S, Kloss F, Dawson R, Narunsky K, Matt L, Wildner L, McHugh TD, Fuhr U, Aldana BH, Mouhdad C, Brake LT, Boeree MJ, Aarnoutse RE, Svensson EM, Gong X, P J Phillips P, Diacon AH, Hoelscher M; PanACEA-TB consortium. Heinrich N, et al. Lancet Microbe. 2025 Feb;6(2):100952. doi: 10.1016/j.lanmic.2024.07.015. Epub 2025 Jan 7. Lancet Microbe. 2025. PMID: 39793592 Free article. Clinical Trial.
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.
Minja LT, van der Feltz I, Manyama C, Mpagama S, Mhimbira F, Noreña I, Sebe M, Rassool M, Wallis RS, Ntinginya N, Liyoyo A, Mbeya B, Wagnerberger L, Zumba T, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut JA, Aarnoutse R, McHugh TD, Wildner L, Boeree MJ, Geiter L, Cho YL, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N; PanACEA consortium. Minja LT, et al. Among authors: manyama c. Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00289-0. doi: 10.1016/S1473-3099(25)00289-0. Online ahead of print. Lancet Infect Dis. 2025. PMID: 40645198 Free article.
Protein binding of rifampicin is not saturated when using high-dose rifampicin.
Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM; PanACEA-MAMS-TB-01 Team. Litjens CHC, et al. J Antimicrob Chemother. 2019 Apr 1;74(4):986-990. doi: 10.1093/jac/dky527. J Antimicrob Chemother. 2019. PMID: 30597025 Clinical Trial.
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials.
Musisi E, Wyness A, Eldirdiri S, Dombay E, Mtafya B, Ntinginya NE, Heinrich N, Kibiki GS, Hoelscher M, Boeree M, Aarnoutse R, Gillespie SH, Sabiiti W; PanACEA consortium. Musisi E, et al. Lancet Microbe. 2023 Nov;4(11):e913-e922. doi: 10.1016/S2666-5247(23)00191-X. Epub 2023 Oct 10. Lancet Microbe. 2023. PMID: 37832571 Free PMC article.
16 results